Anticoagulant treatment for a heart clot after a heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This trial studies whether a specific blood thinner can better treat a left-side heart clot found soon after a heart attack. It may help prevent the clot from getting worse or causing complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a heart attack with ST-segment elevation within the last 7 days
- A left ventricular heart clot was seen on an ultrasound (TTE) or heart MRI (CMR)
- You are currently taking two anti-platelet medicines for heart protection
- You do not need other blood thinners for conditions like atrial fibrillation (AF) or a blood clot in the leg (DVT)
- You are not planned for major heart surgery (like CABG or a valve replacement) within the next 12 months
- You have no reasons you cannot take blood thinners, no prior brain bleeding, and you can agree to take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how to use a blood thinner in people after a recent heart attack who have a clot in the left heart chamber confirmed by heart MRI. It may help lower the risk of the clot causing serious complications, but it also requires careful bleeding-safety screening.
This study looks at whether taking blood thinners for a shorter or longer time is better for people with a blood clot in the heart. It will help doctors decide the right treatment duration to prevent serious complications.
This trial tests whether a newer blood thinner, apixaban, works better than the standard warfarin for treating blood clots in the left ventricle after a heart attack. The goal is to see which medication is safer and more effective at preventing complications.
This trial compares the blood thinner apixaban to warfarin for treating blood clots in the main pumping chamber of the heart (left ventricle). The goal is to see which medicine is better at preventing strokes and other complications.
This trial tests a blood thinner, rivaroxaban, to see if it can prevent blood clots from forming in the heart after a specific type of heart attack (STEMI) that affects the front part of the heart.
This trial tests whether a blood thinner called rivaroxaban helps improve slow blood flow in heart arteries after a stent placement for a heart attack. It may help reduce complications by keeping the arteries open better.
Hear when a new ST-segment Elevation Myocardial Infarction (STEMI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.